Trial · NCT00436215
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
NCT00436215, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer. Trials, record NCT00436215. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00436215
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
- NCT number
- NCT00436215
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Bevacizumab, BAY 43-9006
- First posted
- 2007-02-19
- Last updated
- 2020-11-23
- Results first posted
- 2015-03-26
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Response Rate. | patients were followed for a median of 18 weeks (range 1-116 weeks) | Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. |
| Secondary | Progression-free Survival | up to 28 months | Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. |
| Secondary | Number of Participants With Adverse Events | up to 28 months | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Response Rate. | patients were followed for a median of 18 weeks (range 1-116 weeks) | Seven patients were not evaluable for response assessment. | percentage of participants | NUMBER |
| SECONDARY | Progression-free Survival | up to 28 months | Weeks | MEAN | |
| SECONDARY | Number of Participants With Adverse Events | up to 28 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Response Rate. | BAY 43-9006 + Bevacizumab | Complete Response | 0 | percentage of participants | |
| Clinical Response Rate. | BAY 43-9006 + Bevacizumab | Partial Response | 19 | percentage of participants | |
| Clinical Response Rate. | BAY 43-9006 + Bevacizumab | Progressive Disease | 21 | percentage of participants | |
| Clinical Response Rate. | BAY 43-9006 + Bevacizumab | Stable Disease | 60 | percentage of participants | |
| Progression-free Survival | BAY 43-9006 + Bevacizumab | 26 | Standard Deviation 24 | Weeks | |
| Number of Participants With Adverse Events | BAY 43-9006 + Bevacizumab | 54 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | BAY 43-9006 + Bevacizumab | 55 | |
| Overall Study | COMPLETED | BAY 43-9006 + Bevacizumab | 51 | |
| Overall Study | NOT COMPLETED | BAY 43-9006 + Bevacizumab | 4 |
Source ClinicalTrials.gov
Adverse events199
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | BAY 43-9006 + Bevacizumab | 1 | 55 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | BAY 43-9006 + Bevacizumab | 14 | 55 | 16 |
| other | Activated partial thromboplastin time prolonged | Investigations | BAY 43-9006 + Bevacizumab | 20 | 55 | 38 |
| other | Agitation | Psychiatric disorders | BAY 43-9006 + Bevacizumab | 1 | 55 | 1 |
| other | Alanine aminotransferase increased | Investigations | BAY 43-9006 + Bevacizumab | 30 | 55 | 58 |
| other | Alkaline phosphatase increased | Investigations | BAY 43-9006 + Bevacizumab | 23 | 55 | 46 |
| other | Allergic reaction | Immune system disorders | BAY 43-9006 + Bevacizumab | 2 | 55 | 2 |
| other | Allergic rhinitis | Immune system disorders | BAY 43-9006 + Bevacizumab | 7 | 55 | 8 |
| other | Alopecia | Skin and subcutaneous tissue disorders | BAY 43-9006 + Bevacizumab | 6 | 55 | 6 |
| other | Anal fistula | Gastrointestinal disorders | BAY 43-9006 + Bevacizumab | 1 | 55 | 1 |
1 to 10 of 199Source ClinicalTrials.gov
See all 199 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | BAY 43-9006 + Bevacizumab | 1 | 55 |
| Total, other adverse events | BAY 43-9006 + Bevacizumab | 54 | 55 |
| Total, serious adverse events | BAY 43-9006 + Bevacizumab | 25 | 55 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00436215
GET https://conductscience.org/api/trials/v1/NCT00436215/events?page=2